PetMed Express, Inc. (NASDAQ:PETS) Q1 2022 Earnings Conference Call July 26, 2021 8:30 AM ET Company Participants Bruce Rosenbloom - Chief Financial Officer Gian Fulgoni - Chairman of the Board Conference Call Participants Ben Rose - Battle Road Research Erin Wright - Credit Suisse Anthony Lebiedzinski - Sidoti & Company Operator Welcome to the 1-800-PetMeds Conference Call to Review the Financial Results for the First Fiscal Quarter ended on June 30, 2021. At the request of the Company, this conference cal ...

Financial Data and Key Metrics Changes - For the first quarter of fiscal 2023, sales were $70.2 million, a decrease of 11.5% compared to $79.3 million for the same period last year [22][40] - Net income was $2.8 million or $0.14 diluted earnings per share, down from $4.4 million or $0.22 diluted earnings per share year-over-year [61] - Adjusted EBITDA for the first quarter was $6.3 million, or $0.31 on a diluted basis, compared to $7.1 million or $0.35 on a diluted basis for the same quarter last year [61] Business Line Data and Key Metrics Changes - Reorder sales decreased by 7.8% to $63.3 million for the quarter ended June 30, 2022, compared to $68.7 million for the same quarter the prior year [40] - The AutoShip subscription program saw an increase in adoption, with approximately 34% of revenue derived from this program during the June quarter [51][57] Market Data and Key Metrics Changes - The total U.S. pet market is over $100 billion in annual sales and is expected to reach $120 billion by 2024, with the addressable pet medication market at approximately $10 billion [25] - The company operates in a resilient market, with pet ownership in U.S. households increasing over time, currently at seven out of ten households [34] Company Strategy and Development Direction - The company is transitioning from a focus on existing customers to also generating new customer acquisition, particularly through the AutoShip program and telemedicine initiatives [50][64] - A strategic partnership with Vetster aims to enhance telemedicine capabilities, integrating virtual vet services into the company's offerings [26][45] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a slow start to the flea and tick season due to colder temperatures but noted a rebound in sales as temperatures warmed [2][70] - The company remains optimistic about new customer acquisition initiatives and expects improvements in the upcoming quarters [88] Other Important Information - The company has a strong balance sheet with approximately $105.4 million in cash and cash equivalents and no debt as of June 30, 2022 [9][43] - The Board of Directors declared a quarterly dividend of $0.30 per share, payable on August 19, 2022 [15] Q&A Session Summary Question: What does the seasonal mix look like this year compared to historical trends? - Management noted a slow start to the quarter but observed a rebound in sales through May and June, indicating recovery in the parasiticide business [70] Question: How is the company addressing customer behavior in a tougher macro backdrop? - Management indicated that brand loyalty remains strong, with minimal evidence of customers trading down in prescription medications [84][85] Question: Can you provide details on new customer growth for the quarter? - The company reported acquiring approximately 69,000 new customers during the quarter [86] Question: How is the inventory situation given ongoing supply chain issues? - Management stated that inventory levels are normalized and that direct relationships with manufacturers help mitigate supply chain concerns [110]

PetMed Express, Inc. (NASDAQ:PETS) Q2 2023 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Matthew Hulett - President and CEO Christine Chambers - CFO Brian Prenoveau - IR Conference Call Participants Corey Grady - Jefferies Anthony Lebiedzinski - Sidoti & Company Operator Welcome to PetMed's Conference Call to Review the Financial Results for the Second Fiscal Year ended September 30, 2022. At the request of the company, this call is being recorded. Founded in 1996, PetMed is your ...

PetMed Express, Inc. (NASDAQ:PETS) Q3 2023 Earnings Conference Call February 6, 2022 4:30 PM ET Company Participants Brian Prenoveau - IR Matthew Hulett - President & CEO Christine Chambers - CFO Conference Call Participants Erin Wright - Morgan Stanley Corey Grady - Jefferies Anthony Lebiedzinski - Sidoti & Company Operator Good afternoon, everyone, and thank you for joining the PetMed Express Third Quarter Earnings Conference Call. My name is Doug, the operator for today's call. I would now like to pass t ...

NASDAQ: PETS Safe Harbor & Non-GAAP Measures 2 Your Trusted Pet Health Expert 3 VISION Every pet deserves to live a long, happy, healthy life Corporate Overview Vision: Founded in 1996, PetMeds is "Your Trusted Pet Health Expert" providing fast, easy and helpful service to over 11 million customers across the U.S. Company Highlights • Closed acquisition of PetCareRx in April 2023 • Strategic Initiatives in Pet Telemedicine (Vetster) and Pet insurance (Pumpkin) • AutoShip & Save increased to 44% of total rev ...

PetMed Express, Inc. (NASDAQ:PETS) Q4 2023 Earnings Conference Call May 22, 2023 4:30 PM ET Company Participants Brian Prenoveau - IR, MZ Group Matthew Hulett - President & CEO Christine Chambers - CFO Conference Call Participants Corey Grady - Jefferies Anthony Lebiedzinski - Sidoti & Company Operator Good afternoon, everyone, and thank you for joining the PetMed Express Third Quarter (sic) [Fourth Quarter] Earnings Conference Call. My name is Doug, the operator for today's call. I would now like to pass t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 000-28827 _____________________________________________________________________ PETMED EXPRESS, INC. (Exact nam ...

PetMeds 2.0 1) Adjusted EBITDA and adjusted EBITDA per share are non-GAAP financial measures. See "Non-GAAP Financial Measures" for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures. 12 Investment Highlights Expert well-known online pet pharmacy with over 2 million unique customers Strong market demand for pet medication in pet category resilient to economic headwinds Broader strategic plan – expansion of new customers, more products, unique and ...

Washington D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the transition period from _____________ to _____________ Commission file number: 000-28827 ________________________ PETMED EXPRESS, INC. (Exact name of registrant as specified in its ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Mark One) Washington D.C. 20549 For the transition period from _____________ to _____________ Commission file number: 000-28827 ________________________ PETMED EXPRESS, INC. (Exact name of registrant as specified in its charter) ________________________ (State or other jurisdiction of incorporation or organization) FLORIDA 65-0680967 (I.R.S. Employer Identification No.) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A ...